{"entity":{"type":"insider","cik":"0001929422","url":"/insider/0001929422","json_url":"/insider/0001929422.json","name":"Hannah Brendan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":2,"first":"2023-08-09","last":"2024-08-21","span_basis":"filed_date"},"name_variants":[{"name":"Hannah Brendan","source":"filing","n_filings":2,"first_seen":"2023-08-09","last_seen":"2024-08-21"}],"transactions":[{"id":2132646,"accession":"0001415889-24-021869","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-021869","line_url":"/filing/0001415889-24-021869","is_derivative":false,"issuer_cik":"0001662774","issuer_name":"Quince Therapeutics, Inc.","issuer_ticker":"QNCX","issuer_name_source":null,"issuer_url":"/issuer/0001662774","owner_cik":"0001929422","owner_name":"Hannah Brendan","owner_display_name":"Hannah Brendan","owner_url":"/insider/0001929422","role":"Officer (CHIEF BUSINESS OFFICER AND COO)","role_mark":"O","role_mark_label":"Officer (CHIEF BUSINESS OFFICER AND COO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF BUSINESS OFFICER AND COO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30845.0,"shares_display":"30,845","price_per_share":0.6269006321932242,"price_display":"0.63","price_state":"stated","total_value":19336.75,"total_display":"19,336.75","total_whole":"19,337","shares_owned_after":296540.0,"shares_owned_after_display":"296,540","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-21","filed_date":"2024-08-21","scope":"insider","n_lines":3},{"id":2132632,"accession":"0001415889-24-021869","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-021869","line_url":"/filing/0001415889-24-021869","is_derivative":false,"issuer_cik":"0001662774","issuer_name":"Quince Therapeutics, Inc.","issuer_ticker":"QNCX","issuer_name_source":null,"issuer_url":"/issuer/0001662774","owner_cik":"0001929422","owner_name":"Hannah Brendan","owner_display_name":"Hannah Brendan","owner_url":"/insider/0001929422","role":"Officer (CHIEF BUSINESS OFFICER AND COO)","role_mark":"O","role_mark_label":"Officer (CHIEF BUSINESS OFFICER AND COO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF BUSINESS OFFICER AND COO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5924.0,"shares_display":"5,924","price_per_share":0.6042201215395003,"price_display":"0.60","price_state":"stated","total_value":3579.4,"total_display":"3,579.40","total_whole":"3,579","shares_owned_after":265695.0,"shares_owned_after_display":"265,695","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-20","filed_date":"2024-08-21","scope":"insider","n_lines":2},{"id":2132627,"accession":"0001415889-24-021869","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-021869","line_url":"/filing/0001415889-24-021869#line-1","is_derivative":false,"issuer_cik":"0001662774","issuer_name":"Quince Therapeutics, Inc.","issuer_ticker":"QNCX","issuer_name_source":null,"issuer_url":"/issuer/0001662774","owner_cik":"0001929422","owner_name":"Hannah Brendan","owner_display_name":"Hannah Brendan","owner_url":"/insider/0001929422","role":"Officer (CHIEF BUSINESS OFFICER AND COO)","role_mark":"O","role_mark_label":"Officer (CHIEF BUSINESS OFFICER AND COO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF BUSINESS OFFICER AND COO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2155.0,"shares_display":"2,155","price_per_share":0.58,"price_display":"0.58","price_state":"stated","total_value":1249.9,"total_display":"1,249.90","total_whole":"1,250","shares_owned_after":259771.0,"shares_owned_after_display":"259,771","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-19","filed_date":"2024-08-21","scope":"insider"},{"id":8440114,"accession":"0001209191-23-045234","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-045234","line_url":"/filing/0001209191-23-045234#line-1","is_derivative":false,"issuer_cik":"0001662774","issuer_name":"Quince Therapeutics, Inc.","issuer_ticker":"QNCX","issuer_name_source":null,"issuer_url":"/issuer/0001662774","owner_cik":"0001929422","owner_name":"Hannah Brendan","owner_display_name":"Hannah Brendan","owner_url":"/insider/0001929422","role":"Officer (Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Business Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":71762.0,"shares_display":"71,762","price_per_share":1.22,"price_display":"1.22","price_state":"stated","total_value":87549.64,"total_display":"87,549.64","total_whole":"87,550","shares_owned_after":201555.0,"shares_owned_after_display":"201,555","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-08","filed_date":"2023-08-09","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":7,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":7,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":7},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001662774","name":"Quince Therapeutics, Inc.","url":"/issuer/0001662774","role":"Officer (CHIEF BUSINESS OFFICER AND COO)","n_filings":2,"first_seen":"2023-08-09","last_seen":"2024-08-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001929422","retrieved_at":"2026-08-23T14:20:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}